Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard W Joseph

Showing results (11-20 of 86) with videos related to

Pageof 9
Sort By:
Frontiers in Oncology|June 26, 2026
Pilot study of topical imiquimod combined with pembrolizumab for unresectable cutaneous metastatic melanomaJoseph B Parker, Richard W Joseph, Vera J Suman, et al.
Rare Tumors|April 29, 2015
Whole exome sequencing of a patient with metastatic hidradenocarcinoma and review of the literatureEva Gupta, Kimberly J Guthrie, Murli Krishna, et al.
Melanoma Research|May 4, 2016
Treatment of in-transit and metastatic melanoma in two patients treated with ipilimumab and topical imiquimodRichard W Joseph, Mark Cappel, Katherine Tzou, et al.
Cancer Nursing|October 28, 2017
Patient and Oncology Nurse Preferences for the Treatment Options in Advanced Melanoma: A Discrete Choice ExperimentFrank Xiaoqing Liu, Edward A Witt, Scot Ebbinghaus, et al.
Patient Preference and Adherence|September 2, 2017
Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experimentFrank Xiaoqing Liu, Edward A Witt, Scot Ebbinghaus, et al.
Cancer Immunology Research|October 8, 2014
Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapyRichard W Joseph, Mark Cappel, Brent Goedjen, et al.
European Urology Oncology|October 23, 2018
Adjuvant Antiangiogenic Agents in Post-nephrectomy Renal Cell Carcinoma: A Systematic Review and Meta-analysisMohamad B Sonbol, Belal Firwana, Talal Hilal, et al.
Immunotherapy|November 9, 2018
Factors associated with immunotherapy selection in patients with advanced melanomaRichard W Joseph, Alicia C Shillington, Cynthia Macahilig, et al.
Frontiers in Oncology|April 7, 2018
Association Between Programmed Death-Ligand 1 Expression and the Vascular Endothelial Growth Factor Pathway in AngiosarcomaSanjay P Bagaria, Zoran Gatalica, Todd Maney, et al.
BMC Urology|February 1, 2014
ANKS1B is a smoking-related molecular alteration in clear cell renal cell carcinomaJeanette E Eckel-Passow, Daniel J Serie, Brian M Bot, et al.
Pageof 9

Showing results (11-20 of 86) with videos related to

Sort By:
Pageof 9
Frontiers in Oncology|June 26, 2026
Pilot study of topical imiquimod combined with pembrolizumab for unresectable cutaneous metastatic melanomaJoseph B Parker, Richard W Joseph, Vera J Suman, et al.
Rare Tumors|April 29, 2015
Whole exome sequencing of a patient with metastatic hidradenocarcinoma and review of the literatureEva Gupta, Kimberly J Guthrie, Murli Krishna, et al.
Melanoma Research|May 4, 2016
Treatment of in-transit and metastatic melanoma in two patients treated with ipilimumab and topical imiquimodRichard W Joseph, Mark Cappel, Katherine Tzou, et al.
Cancer Nursing|October 28, 2017
Patient and Oncology Nurse Preferences for the Treatment Options in Advanced Melanoma: A Discrete Choice ExperimentFrank Xiaoqing Liu, Edward A Witt, Scot Ebbinghaus, et al.
Patient Preference and Adherence|September 2, 2017
Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experimentFrank Xiaoqing Liu, Edward A Witt, Scot Ebbinghaus, et al.
Cancer Immunology Research|October 8, 2014
Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapyRichard W Joseph, Mark Cappel, Brent Goedjen, et al.
European Urology Oncology|October 23, 2018
Adjuvant Antiangiogenic Agents in Post-nephrectomy Renal Cell Carcinoma: A Systematic Review and Meta-analysisMohamad B Sonbol, Belal Firwana, Talal Hilal, et al.
Immunotherapy|November 9, 2018
Factors associated with immunotherapy selection in patients with advanced melanomaRichard W Joseph, Alicia C Shillington, Cynthia Macahilig, et al.
Frontiers in Oncology|April 7, 2018
Association Between Programmed Death-Ligand 1 Expression and the Vascular Endothelial Growth Factor Pathway in AngiosarcomaSanjay P Bagaria, Zoran Gatalica, Todd Maney, et al.
BMC Urology|February 1, 2014
ANKS1B is a smoking-related molecular alteration in clear cell renal cell carcinomaJeanette E Eckel-Passow, Daniel J Serie, Brian M Bot, et al.
Pageof 9